Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fucoidan (FCD) shows promise for treating ulcerative colitis (UC) by reducing inflammation and improving gut health. Further clinical trials are needed to confirm its effectiveness as a therapeutic agent for UC.
Area Of Science
- Marine Biotechnology
- Gastroenterology
- Immunology
Background
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited effective treatments.
- Gut dysbiosis, immune dysregulation, and oxidative stress are key drivers of UC pathogenesis.
- Fucoidan (FCD), a sulfated polysaccharide from brown algae, exhibits anti-inflammatory, antioxidant, and immunomodulatory properties.
Purpose Of The Study
- To review the mechanisms by which fucoidan (FCD) impacts ulcerative colitis (UC) pathogenesis.
- To explore FCD's potential as a therapeutic agent for UC.
- To identify challenges and future directions for FCD in UC treatment.
Main Methods
- Review of preclinical studies on fucoidan's effects in UC models.
- Analysis of FCD's impact on inflammatory signaling pathways (NF-κB, MAPK).
- Assessment of FCD's influence on intestinal barrier integrity and gut microbiota composition.
Main Results
- FCD suppresses key inflammatory pathways (NF-κB, MAPK), reducing pro-inflammatory cytokines.
- FCD enhances intestinal barrier function by upregulating tight junction proteins and MUC2.
- FCD promotes beneficial gut bacteria and suppresses pathogens, improving microbial ecology.
Conclusions
- Fucoidan (FCD) demonstrates significant potential as an adjuvant therapy or functional food for ulcerative colitis (UC).
- Low-molecular-weight fucoidan (LMWF) shows enhanced bioavailability and efficacy in preclinical models.
- Further clinical validation and strategies to improve FCD bioavailability are crucial for therapeutic application.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...